WO2001098294A3 - Vitronectin receptor antagonist pharmaceuticals for use in combination therapy - Google Patents

Vitronectin receptor antagonist pharmaceuticals for use in combination therapy Download PDF

Info

Publication number
WO2001098294A3
WO2001098294A3 PCT/US2001/019794 US0119794W WO0198294A3 WO 2001098294 A3 WO2001098294 A3 WO 2001098294A3 US 0119794 W US0119794 W US 0119794W WO 0198294 A3 WO0198294 A3 WO 0198294A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
receptor antagonist
vitronectin receptor
pharmaceuticals
treatment
Prior art date
Application number
PCT/US2001/019794
Other languages
French (fr)
Other versions
WO2001098294A2 (en
Inventor
Milind Rajopadhye
John A Barrett
Alan P Carpenter Jr
Edward H Cheesman
Thomas D Harris
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Priority to AU7002501A priority Critical patent/AU7002501A/en
Priority to AU2001270025A priority patent/AU2001270025B2/en
Priority to EP01948554A priority patent/EP1296678A2/en
Priority to CA002413957A priority patent/CA2413957A1/en
Publication of WO2001098294A2 publication Critical patent/WO2001098294A2/en
Publication of WO2001098294A3 publication Critical patent/WO2001098294A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention describes novel kits and compositions comprising compounds of the formula (I):(Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer in combination therapy in a patient. The present invention provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
PCT/US2001/019794 2000-06-21 2001-06-21 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy WO2001098294A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU7002501A AU7002501A (en) 2000-06-21 2001-06-21 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
AU2001270025A AU2001270025B2 (en) 2000-06-21 2001-06-21 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
EP01948554A EP1296678A2 (en) 2000-06-21 2001-06-21 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
CA002413957A CA2413957A1 (en) 2000-06-21 2001-06-21 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21321200P 2000-06-21 2000-06-21
US60/213,212 2000-06-21

Publications (2)

Publication Number Publication Date
WO2001098294A2 WO2001098294A2 (en) 2001-12-27
WO2001098294A3 true WO2001098294A3 (en) 2003-01-09

Family

ID=22794180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019794 WO2001098294A2 (en) 2000-06-21 2001-06-21 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy

Country Status (4)

Country Link
EP (1) EP1296678A2 (en)
AU (2) AU2001270025B2 (en)
CA (1) CA2413957A1 (en)
WO (1) WO2001098294A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844783B2 (en) 2010-01-28 2023-12-19 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1356913A (en) 1998-12-18 2002-07-03 杜邦药品公司 Vitronectic receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
EP2286843A3 (en) * 2000-06-02 2011-08-03 Bracco Suisse SA Compounds for targeting endothelial cells
MXPA02012750A (en) * 2000-06-21 2004-07-30 Bristol Myers Squibb Pharma Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy.
EP1311292A2 (en) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US20040208844A1 (en) * 2001-08-01 2004-10-21 Francis Ignatious Products and drug delivery vehicles
US7319149B2 (en) * 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
WO2005087210A2 (en) 2004-03-17 2005-09-22 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
PT1717226E (en) * 2004-03-19 2009-04-03 Novartis Ag 2,7-substituted 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octan amide derivatives as renin inhibitors for the treatment of hypertension
CN100471496C (en) * 2004-04-15 2009-03-25 中国人民解放军军事医学科学院毒物药物研究所 Inclusion containing raltitrexed and its powder injection
CN100369606C (en) * 2004-04-15 2008-02-20 中国人民解放军军事医学科学院毒物药物研究所 Inclusion containing raltitrexed and preparation
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
TW200732305A (en) * 2005-12-23 2007-09-01 Yung Shin Pharmaceutical Ind Cancer chemotherapy
US7968536B2 (en) 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
TWI444379B (en) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc Compounds useful as raf kinase inhibitors
FR2942227B1 (en) 2009-02-13 2011-04-15 Guerbet Sa USE OF BUFFERS FOR RADIONUCLEID COMPLEXATION
FR2968999B1 (en) 2010-12-20 2013-01-04 Guerbet Sa CHELATE NANOEMULSION FOR MRI
FR2980364B1 (en) 2011-09-26 2018-08-31 Guerbet NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS
FR3001154B1 (en) 2013-01-23 2015-06-26 Guerbet Sa MAGNETO-EMULSION VECTORIZED
PT3929196T (en) * 2013-09-24 2023-09-11 Fujifilm Corp Novel nitrogen-containing compound or salt thereof, or metal complex thereof
CN107428755B (en) * 2015-03-25 2020-03-03 富士胶片株式会社 Process for producing nitrogen-containing compound or salt thereof, and intermediate for production thereof
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
CN113368235B (en) * 2021-05-11 2022-11-15 上海师范大学 Gd-NGQDs/BTS @ PLGA-PEG nano material and preparation method and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0095906A1 (en) * 1982-05-27 1983-12-07 National Research Development Corporation Improvements relating to compounds useful in radiotherapy or chemotherapy
WO1997023480A1 (en) * 1995-12-22 1997-07-03 The Du Pont Merck Pharmaceutical Company Novel integrin receptor antagonists
EP0819430A1 (en) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibitor of tumor metastasis or recurrence
WO1998047541A1 (en) * 1997-04-24 1998-10-29 Nycomed Imaging As Contrast agents
WO1999006347A1 (en) * 1997-07-31 1999-02-11 Yeda Research And Development Company Ltd. The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
WO1999040947A2 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO1999058162A2 (en) * 1998-03-31 1999-11-18 Du Pont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
WO2000018439A2 (en) * 1998-09-29 2000-04-06 Schering Aktiengesellschaft Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
WO2000035488A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0095906A1 (en) * 1982-05-27 1983-12-07 National Research Development Corporation Improvements relating to compounds useful in radiotherapy or chemotherapy
WO1997023480A1 (en) * 1995-12-22 1997-07-03 The Du Pont Merck Pharmaceutical Company Novel integrin receptor antagonists
EP0819430A1 (en) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibitor of tumor metastasis or recurrence
WO1998047541A1 (en) * 1997-04-24 1998-10-29 Nycomed Imaging As Contrast agents
WO1999006347A1 (en) * 1997-07-31 1999-02-11 Yeda Research And Development Company Ltd. The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
US6229048B1 (en) * 1997-07-31 2001-05-08 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Helianthrone derivatives as anti-cancer agents
WO1999040947A2 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO1999058162A2 (en) * 1998-03-31 1999-11-18 Du Pont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
WO2000018439A2 (en) * 1998-09-29 2000-04-06 Schering Aktiengesellschaft Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
WO2000035488A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D.G. BATT ET AL, J. MED. CHEM., vol. 43, no. 1, 2000, pages 41 - 58, XP000915237 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844783B2 (en) 2010-01-28 2023-12-19 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Also Published As

Publication number Publication date
WO2001098294A2 (en) 2001-12-27
EP1296678A2 (en) 2003-04-02
AU2001270025B2 (en) 2005-08-18
CA2413957A1 (en) 2001-12-27
AU7002501A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2001098294A3 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001097861A3 (en) Vitronectin receptor antagonist pharmaceuticals
WO2001097860A3 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
DE60001983T2 (en) BICYCLIC AND TRICYCLIC HETEROAROMATIC COMPOUNDS
TR199901710T2 (en) IL-8 receptor antagonists.
IL173029A0 (en) Imaging agents
HUP0101468A2 (en) Pharmaceuticals for the imaging of angiogenic disorders
WO2002026776A3 (en) Peptide-based compounds
NZ522326A (en) Adenosine A2A receptor antagonists
BR0116379A (en) Heteroaryl urea neuropeptide γ5 receptor antagonists
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
WO2001097848A3 (en) Vitronectin receptor antagonist pharmaceuticals
EP1372741A4 (en) Morpholino imaging and therapy
TR199900318T2 (en) IL-8 receptor antagonists.
ATE505208T1 (en) RECEPTOR BINDING CONJUGATES
ATE233754T1 (en) DIPHENYL-PIPERIDINE DERIVATIVES
TR200103680T2 (en) IL-8 receptor antagonists.
EA200500882A1 (en) N-ARILSULFONIL-3-AMINOALKOXIINDOLES
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
ATE362772T1 (en) VITRONECTIN RECEPTOR ANTAGONIST DRUGS OR DIAGNOSTICS
WO2000048581A3 (en) Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
MX9703232A (en) Novel muscarinic receptor agonists.
WO2000076457A3 (en) Il-8 receptor antagonists
TR200103690T2 (en) IL-8 receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2413957

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001270025

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001948554

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001948554

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001948554

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001270025

Country of ref document: AU